Entera Bio Management
Management criteria checks 2/4
Entera Bio's CEO is Miranda Toledano, appointed in Jul 2022, has a tenure of 1.75 years. total yearly compensation is $950.00K, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $221.50K. The average tenure of the management team and the board of directors is 3.7 years and 5.3 years respectively.
Key information
Miranda Toledano
Chief executive officer
US$950.0k
Total compensation
| CEO salary percentage | 35.6% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.7yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Mar 23
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
May 31Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
Feb 15Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?
Oct 13Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M
Aug 11We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully
Jun 10Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth
Jan 21We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow
Oct 06Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation
Jun 19Entera Bio secures European patent for oral PTH formulations
Jun 17We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
Mar 20Here's Why Entera Bio (NASDAQ:ENTX) Must Use Its Cash Wisely
Dec 05
Entera Bio EPS misses by $0.22
Nov 19Entera Bio completes enrollment in Phase 2 trial of EB613 in Osteoporosis
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$950k | US$338k | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$795k | US$231k | -US$13m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$82k | n/a | -US$12m |
Compensation vs Market: Miranda's total compensation ($USD950.00K) is above average for companies of similar size in the US market ($USD668.06K).
Compensation vs Earnings: Miranda's compensation has increased whilst the company is unprofitable.
CEO
Miranda Toledano (46 yo)
1.8yrs
Tenure
US$950,000
Compensation
Ms. Miranda J. Toledano, M.B.A. serves as Chief Executive Officer of Entera Bio Ltd. since July 15, 2022. She serves as an Independent Director of Journey Medical Corporation since November 2021.She has b...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$950.00k | 0.31% $ 221.5k | |
| Chief Financial Officer | 1.8yrs | US$311.00k | 0.16% $ 113.2k | |
| Chief Operating Officer | 10.2yrs | US$459.00k | 0.096% $ 68.2k | |
| Chief Medical Officer | 5.6yrs | US$389.00k | 0.84% $ 595.3k |
3.7yrs
Average Tenure
45.5yo
Average Age
Experienced Management: ENTX's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$950.00k | 0.31% $ 221.5k | |
| Member of Clinical & Scientific Advisory Board | less than a year | no data | no data | |
| Independent Chairman of the Board | 10yrs | US$130.97k | 0.71% $ 503.5k | |
| Independent Director | 5.3yrs | US$120.97k | 0.028% $ 20.0k | |
| Director | 8.1yrs | US$115.97k | 0.014% $ 9.9k | |
| Independent Director | 3yrs | US$127.86k | 0.020% $ 14.0k | |
| Independent Director | 13.3yrs | US$252.00k | 0.020% $ 14.5k | |
| Independent Director | less than a year | US$8.61k | 0.051% $ 36.0k | |
| Independent Director | 4.8yrs | US$117.47k | 0.29% $ 204.2k |
5.3yrs
Average Tenure
60yo
Average Age
Experienced Board: ENTX's board of directors are considered experienced (5.3 years average tenure).